Prospective Evaluation of Biliary Tissue Sampling With ERCP

Status Enrolling by invitation

Clinical Trial Summary

The purpose of this study is to assess the safety, outcomes and performance characteristics of multiple biliary sampling techniques including but not limited to: single operator cholangioscopy (SOC) directed biopsies, transpapillary biliary biopsies (TPBx), brushings and bile aspiration for cytology and FISH in patients undergoing ERCP.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Biliary Stricture
Biliary Tract Diseases
Cholangiocarcinoma
Cholangiopancreatography, Endoscopic Retrograde

Clinical Trial Details

NCT number	NCT04572711
Study type	Observational
Source	Mayo Clinic
Contact
Status	Enrolling by invitation
Phase
Start date	September 1, 2020
Completion date	May 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05497531` - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers	N/A
Recruiting	`NCT05678218` - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Recruiting	`NCT06010862` - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors	Phase 1
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Recruiting	`NCT05179486` - Molecular Epidemiology of Biliary Tree Cancers
Suspended	`NCT05124743` - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Terminated	`NCT04304781` - Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer	Phase 1
Completed	`NCT03150615` - Enteral Nutrition After Pancreaticoduodenectomy	N/A
Completed	`NCT01912053` - Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma	Phase 2
Recruiting	`NCT01439698` - Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry	N/A
Terminated	`NCT01434459` - Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin	Phase 1
Completed	`NCT01206049` - Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations	Phase 2
Recruiting	`NCT00973713` - Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol	Phase 2
Terminated	`NCT00975039` - Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma	Phase 2
Completed	`NCT00779454` - Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma	Phase 2
Terminated	`NCT04066491` - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC	Phase 2/Phase 3
Recruiting	`NCT04340986` - Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
Active, not recruiting	`NCT04526106` - REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT03603834` - Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma	Phase 2
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2